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Abstract: Sleep disruption is a prevalent clinical feature in many neurodegenerative disorders,
including human prion diseases where it can be the defining dysfunction, as in the case of
the “eponymous” fatal familial insomnia, or an early-stage symptom as in certain types of
Creutzfeldt-Jakob disease. It is important to establish the role of the cellular prion protein (PrPC),
the key molecule involved in prion pathogenesis, within the sleep-wake system in order to understand
fully the mechanisms underlying its contribution to both healthy circadian rhythmicity and sleep
dysfunction during disease. Although severe disruption to the circadian rhythm and melatonin
release is evident during the pathogenic phases of some prion diseases, untangling whether PrPC
plays a role in circadian rhythmicity, as suggested in mice deficient for PrPC expression, is challenging
given the lack of basic experimental research. We provide a short review of the small amount of
direct literature focused on the role of PrPC in melatonin and circadian rhythm regulation, as well as
suggesting mechanisms by which PrPC might exert influence upon noradrenergic and dopaminergic
signaling and melatonin synthesis. Future research in this area should focus upon isolating the
points of dysfunction within the retino-pineal pathway and further investigate PrPC mediation of
pinealocyte GPCR activity.
Keywords: prion; sleep; circadian rhythm; melatonin; serotonin
1. Introduction
The highly conserved prion protein (PrP) is encoded by the PRNP gene (human cytogenic location
20p12) [1] and exists predominately in two conformationally different isoforms [2]. The cellular prion
protein (PrPC) has an α-helical structure and is expressed highly within the central and peripheral
nervous systems [3] and localized to neuronal and glial cell membranes [4]. PrPC expression has
also been identified in tissues beyond the nervous systems, including the intestine, heart and lymph
nodes [5]. This widespread distribution of apparently functional PrPC, coupled with its highly
conserved nature, suggests that it has either one important role or multiple, context-dependent roles
throughout the body. Total knockout of PrPC is not associated with major deleterious phenotypes [6],
suggesting that the latter hypothesis is more likely to be true. Indeed, PrPC has been implicated
in, among other things, immune response modulation [7], myelin maintenance [8], mitochondrial
homeostasis [9] and signal transduction as reviewed recently by Castle and Gill [4]. A final possibility is
that PrPC does indeed have a single role in a key biochemical pathway that impacts other physiological
processes that PrPC is proposed to control; in this possibility, PrPC may be involved only in modulating
activity of the top-level system rather than turning it on or off, thereby explaining its apparent
redundancy and context-dependent functions. Of relevance to this review is the finding that, in models
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of PrPC dysfunction or knockout, marked alterations to circadian rhythms occur [10] suggesting a role
for PrPC in one of the most essential processes for life: the sleep/wake (or active/rest) cycle.
The prion protein is one of a handful of naturally expressed proteins that can misfold into
specific pathogenic isoforms and, hence, become integral to neurodegenerative phenotypes. The prion
protein’s conformationally-altered isoform is known as PrPSc, which is enriched in β-sheet structure,
is insoluble and which assembles into amyloid plaques and fibrils [11]. The conversion from PrPC to
PrPSc and the subsequent aggregation and oligomerization of PrPSc results in severe, and ultimately
fatal, neurodegenerative prion diseases, also known as transmissible spongiform encephalopathies
or TSEs [11,12]. Prion diseases can occur sporadically, due to infection, or as the result of genetic
influence [13]. The exact mechanism underlying sporadic conversion from PrPC to PrPSc is unknown,
but it is believed that this mechanism is expedited when PrPC contains a disease-initiating mutation.
However, following the initiation of an infection (e.g., by ingesting contaminated meat) exogenous
PrPSc is believed to be used as a template, upon which the functional endogenous PrPC misfolds
in a process of autocatalytic conversion [11,12]. The incubation period between inoculation and
disease onset is prolonged in prion diseases [11], providing a potential window for neuroprotective
interventions [14], but this relies on knowledge of the molecular mechanisms responsible for neuronal
loss so that intervention can be targeted effectively and specifically. Identifying such mechanisms
is complicated by the fact that different prion disease types (or strains) target pathology to rather
different areas of the brain and the information that causes neuropathological targeting is believed
to be encoded in the structure of PrPSc. Although multimeric forms of PrPSc may be toxic to neurons
directly, by activating signaling pathways that lead to apoptosis or necrosis, it is also possible that
the neuropathology that arises with PrPSc propagation occurs in combination with loss of function
of PrPC [15]. Indeed, during pathogenesis of a prion disease, PrPC expression has been suggested to
be downregulated [15,16]. Herein we review whether there may be role for PrPC loss of function in
the sleep-wake cycle, a key biological system that is compromised to different extents during various
prion diseases.
2. Sleep Dysfunction during Prion Disease Pathogenesis
Observations of human prion disease patients provided the first links between PrPC/PrPSc and
sleep. In the genetic prion disease fatal familial insomnia (FFI), the “eponymous” clinical feature is
severely disturbed sleep, characterized by anxiolytic-resistant insomnia, circadian rhythm dysfunction,
sleep fragmentation and altered arousal. Polysomnographic studies show a decrease in total sleep
time, decreased REM sleep and loss of REM atonia [17]. Central sleep apneas and decreased slow
wave sleep are also common features of FFI clinicopathology [18]. These extensive symptoms are likely
to be the result of dysfunction across the various systems regulating sleep.
To variable degrees, sleep disturbances are also evident in other prion diseases, including various
human prion diseases, although they are not currently considered part of the clinical diagnostic criteria.
Nevertheless, in a recent study almost 90% of sporadic Creutzfeldt-Jakob disease (spCJD) patients
reported sleep dysfunction during clinical evaluation, making sleep disturbance more prevalent than
any other diagnostic criteria for CJD [19]. Sleep disturbances were also prevalent clinical complaints in
all familial CJD patients examined during a separate study [20]. Certain animal models of prion disease
also result in disrupted sleep patterns; rats inoculated with various prion strains have pronounced slow
wave sleep decreases [21], rhesus monkeys infected with the human prion disease kuru show complete
loss of REM sleep and disrupted sleep stage cycling [22], whilst mice inoculated with the murine prion
disease RML show alterations in rest period activity from extremely early in the incubation period [23].
Interestingly, it has been reported that patients with Gerstmann-Sträussler-Sheinker disease (a genetic
prion disease characterized predominantly by ataxia and pyramidal dysfunction) do not exhibit sleep
alterations [24,25], suggesting that sleep dysfunction is specific to particular prion strains. Given that
neuropathology in different prion strains is targeted to different regions of the brain, it follows that
molecular or cellular alterations in specific brain regions may underlie some of the prion-induced sleep
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abnormalities. It is pertinent, therefore, to consider the brain areas that control the different aspects of
normal sleep and how these are affected during prion pathogenesis.
The slow wave oscillations of deep, non-REM (NREM sleep) are generated, synchronized and
stabilized by the thalamocortical network [26,27], whilst fluctuations in thalamocortical excitability
produces the hallmark deflections visualized on EEG traces during NREM sleep: the K-complex and
sleep spindle [28]. Cortically-generated K-complexes occur both spontaneously and in response to
sensory stimulation, acting to monitor environmental stimuli during reduced states of consciousness
and to enhance sleep stability [28]. The K-complex waveform is reflected in thalamic activity,
with thalamic neurons reinforcing the K-complex slow oscillation [26]. In response to the K-complex,
thalamic reticular neurons generate their own oscillation—known as the sleep spindle—which is
thought to be instrumental in thalamocortical plasticity, cognition and memory function [29]. One of
the most striking polysomnographic observations in FFI and fCJD patients is a reduction or absence of
the thalamocortical K-complex and sleep spindle oscillations [19,30–32]. Prion-induced dysregulation
of slow wave sleep, sleep instability and the loss of K-complex and sleep spindle oscillations (as well
as the memory and cognitive impairments seen in prion diseases) are therefore likely due to the
gross neurodegeneration of the thalamocortical network as the disease process reaches the clinical
phase [33]. Support for this rationale comes from mouse models of FFI: mice expressing PrPC carrying
the D178N mutation (that causes FFI in humans in combination with methionine expressed at codon
129) develop thalamic pathology and exhibit disrupted circadian rhythmicity of sleep and motor
activity. Both over-expressing [34] and knock-in [35] FFI transgenic mice are phenotypically similar to
human FFI patients, with the overexpressing mice exhibiting abnormal REM-sleep transitioning, loss of
sleep spindles, reduced slow wave activity and decreased sleep continuity. Anatomically, these mice
also exhibited thalamic degeneration, which, as in human patients, is responsible for the observed
breakdown of sleep architecture. However, changes in circadian-regulated motor activity of these
mice, including decreased dark-phase activity compared to controls [34], are not readily rationalized
by thalamic degeneration and knock-in FFI mice also show significant decreases in dark-phase motor
activity compared to controls [35].
Symptoms of insomnia reported by prion disease patients can be explained by the reduction in
both sleep stability and sleep maintenance associated with thalamocortical degeneration. It is also
likely that the dysregulation of circadian rhythmicity seen in prion disease contributes to symptoms
of insomnia. A key organ responsible for the modulation of sleep patterns through synthesis of the
circadian hormone melatonin is the pineal gland, and it has been demonstrated that non-prion patients
with insomnia exhibit reduced pineal gland volume [36] as well as significantly decreased nocturnal
plasma melatonin levels [37]. The pineal gland is a site of high level expression of PrPC [4]. Whilst this
may render the pineal gland highly susceptible to infection by prions, it also raises the possibility that
reduced levels of functional PrPC during a prion infection [15] may be involved in sleep dysfunction.
Thus, the mechanisms of circadian dysfunction evident in prion diseases require further basic science
investigation beyond clinical reporting, as currently there is little known of how a prion infection can
dysregulate such an essential system.
3. Circadian Rhythm, Homeostatic Sleep Pressure and Melatonin
The sleep-wake cycle is driven by two factors: circadian rhythm and homeostatic sleep
pressure [38,39]. Homeostatic sleep pressure is best described as the feeling of sleepiness, such that the
longer one goes without sleep, the more tired one becomes. The driving mechanism of homeostatic
sleep pressure is thought to be the result of chemical build-up, such as increased levels of adenosine [40],
within the brain. Slow wave oscillations during wakefulness and sleep are regulated homeostatically,
with slow wave activity decreasing over the sleep period and increasing as time awake increases [41,42].
Similar to homeostatic sleep pressure, circadian rhythmicity is the result of endogenous processes,
with every cell exhibiting its own intrinsic, oscillatory, circadian rhythm [43]. The oscillations in cellular
gene expression, caused by a negative feedback transcription/translation loop, have a natural period
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of around 24 h, but are then synchronized to the exogenous light/dark cycle [43]. The circadian rhythm
is also modulated, to a degree, by other external factors such as exercise and food consumption [44] as
well as internal factors including core body temperature and the menstrual cycle [45].
The main regulatory hormone of the circadian rhythm is melatonin [39]. Melatonin is part of
the tryptophan metabolic pathway [42] and it is synthesized and secreted by both central nervous
system (CNS) tissues and organs throughout the body [46]. Within the CNS, melatonin production
is entrained to the light/dark cycle, with the hormone acting as a mediator between hypothalamic
nuclei and target tissues, relaying diurnal and seasonal timings to the body [47]. As with PrPC,
the variety of organs capable of melatonin synthesis is suggestive of important, contextual roles
for this hormone, including regulation of seasonal and circadian rhythms, reproductive function,
modulation of neurotransmission and antioxidant effects [47].
The complex, multi-nuclei pathway for melatonin synthesis, depicted schematically in Figure 1,
begins with blue light excitation of photosensitive, melanopsin-containing retinal ganglion cells (RGCs).
The RGC axons form the retino-hypothalamic tract which projects to the hypothalamic suprachiasmatic
nucleus (SCN), providing glutamatergic excitation of SCN neurons. The SCN is the central pacemaker
that fine-tunes the body’s circadian rhythm, conveying the light/dark fluctuations of the external
environment to various tissues, including the brain, via oscillatory activity in order to coordinate
metabolic function and homeostasis accordingly [48]. These SCN oscillations are generated in response
to RCG neurotransmission by a transcriptional-translational feedback loop between clock genes [49].
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Figure 1. The Retino-Pineal Pathway. tr ct res d athways in yellow represent light-active
regions, those in dark blue represent dark-active regions. rrows represent direction of signaling;
associated text represents main neurotransmitters in the pathway. Region abbreviations: RCGs retinal
ganglion cells; SCN suprachiasmatic nucleus; PVN paraventricular nucleus; IML intermediolateral nucleus;
SCG superior cervical ganglion; PG pineal gland. Neurotransmitter abbreviations: GLU glutamate;
PACAP pituitary adenylate-cyclase activating peptide; GABA gamma-aminobutyric acid; OT oxytocin;
VP vasopressin; ACh acetylcholine; NA noradrenaline.
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In all melatonin-synthesizing organisms, light acts as a zeitgeber (environmental cue) for
melatonin secretion, with peak melatonin levels arising in the middle of the night’s sleep at
approximately 100 times the daytime melatonin level [39]. In daylight, GABAergic SCN projections
synapse to paraventricular (PVN) neurons, inhibiting further excitation of the pathway. At night,
without RCG/SCN excitation, PVN neurons are disinhibited, leading in turn to excitation of thoracic
intermediolateral (IML) neurons and superior cervical ganglia (SCG) neurons. Noradrenergic
SCG neurons project to the pineal gland, which expresses both α1 and β1-adrenoceptors [50].
Noradrenaline-adrenoceptor binding then activates adenylate cyclase and the melatonin synthesis
cascade within pinealocytes.
Pinealocytes provide the majority of circulating melatonin, with immediate melatonin release into
the blood (bypassing the blood brain barrier) and into CSF circulation at the point of the pineal recess
and third ventricle [51]. Melatonin travels via CSF and blood to target tissues expressing G-protein
coupled melatonin receptors MT1 and MT2 [52]. MT1 binding has been associated with metabolic
regulation, whilst MT2 binding is associated with circadian rhythmicity [46]. Expression of both
melatonin receptors is widespread throughout the brain, with localization to neurons of the SCN,
thalamus and hippocampus, amongst other structures [41].
The pineal gland is not the only source of melatonin; extrapineal melatonin synthesis is thought
to occur in a number of organs that express melatonin-synthesizing enzymes, including the heart,
liver and placenta [46]. Indeed, the gut expresses melatonin levels 400 times greater than that of
the pineal gland, and extrapineal melatonin synthesis has been shown to occur independently of
the photoperiod, with an absence of diurnal fluctuations [53]. In contrast to the pineal-synthesized
melatonin, which is immediately released into CSF and blood circulation, melatonin synthesized in
tissues beyond the CNS is retained within cells [46]. Intracellular melatonin is correlated with its
local anti-inflammatory/oxidative effects; in neonates with respiratory distress syndrome, melatonin
treatment significantly reduces pro-inflammatory cytokine and nitrate levels [54], whilst melatonin
levels in the elderly are inversely correlated with Charlson Comorbidity Index score, indicating a
protective role against chronic disease [55].
Abolition of endogenous CNS melatonin has far-reaching consequences for the brain and body;
reports of impaired wound healing [56], disrupted circadian organization of the SCN [57], abolition of
clock gene expression in adipose tissue [58] as well as altered bone metabolism leading to bone loss [59]
provide evidence for the protective function of melatonin in health. The effects of pinealectomy upon
sleep are equally as wide-ranging. Long-term changes post-pinealectomy in humans include reduced
sleep efficiency and increased switching between sleep stages, indicating a role for melatonin in sleep
stability [60]. Pinealectomized rats show a significant decrease in REM-sleep theta power compared to
controls [61]. Intriguingly, there are also reports of the loss of hippocampal CA1 and CA3 neurons
post pinealectomy in rats [62], which can be reversed by administering exogenous melatonin; since
MT1/MT2-expressing hippocampal CA1 and CA3 neurons [63] generate cortical theta oscillations,
the theta reduction in pinealectomized rats may be, in part, the result of the hippocampal pyramidal
neuron loss.
Extrapolating the influence of melatonin upon the CNS and body is challenging, given how
intertwined the circadian rhythm is with whole-system function. It is important to identify whether
prion disease-related sleep/wake dysfunctions are the result of circadian rhythm anomalies caused by
PrPC loss of function from the pineal gland, whether anomalies can be explained by neurodegeneration
caused by PrPSc-mediated neurotoxicity or whether both affects play a role. This requires a
consideration of the link between PrPC, circadian rhythms and melatonin signaling.
4. A Role for PrPC in the Regulation of Melatonin Synthesis
Early research revealed that PrP mRNA expression peaks during the circadian dark phase
at approximately 14 h (zeitgeber time) [64]. This significant increase in PrP mRNA expression
precedes melatonin synthesis, with pineal melatonin levels increasing to a peak from 18 to 20 h
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(zeitgeber time) [65]. Whilst the apparent correlation between PrPC and melatonin levels may be just
that—correlative rather than causative—there is some evidence that PrPC levels impact directly or
indirectly on melatonin levels and that the high level of PrPC expression in the pineal glands may play
a role in regulating melatonin synthesis.
Early studies of PrP knockout (PrP−/−) mice highlighted similar sleep disruptions to those
reported in human prion disease cases, such as increased sleep fragmentation and altered slow wave
activity [10]. It was noted that PrP−/− mice exhibited a significantly longer circadian phase than
controls (23.9 h vs. 23.3 h, respectively), as well as demonstrating inverse dark phase activity compared
to controls; control mice carried out the majority of their wheel-running during the first half of the dark
phase, whilst PrP−/− mice had increased activity towards the end of the dark phase [10]. These findings
suggest PrP−/− mice experience a phase shift in their circadian timings, akin to that seen in delayed
phase sleep disorders, with circadian period elongation and delay in activity timings [66]. It was also
noted that PrP−/− mice exhibited alterations to intrinsic circadian rhythms. Normally, in the complete
absence of light, the circadian rhythm deregulates and becomes “free-running”, which manifests in
incremental shifts in peak melatonin release from night to day [67], since intrinsic circadian rhythms in
mice are slightly greater than 24 h. When placed in complete darkness, control mice exhibited this
free-running circadian rhythm, using motor activity as an indicator, whilst, confusingly, the PrP−/−
mice maintained 24 h rhythmicity despite no light entrainment [10]. Further to this, PrP−/− mice
demonstrate non-cyclical, phase-shifted melatonin release in comparison to controls, with no increase
in nighttime plasma melatonin level but increased levels of melatonin during the day relative to
controls [68].
The above observations beg the question of whether PrPC functions as part of the pathway that
turns light cues into melatonin and suggest that disruption of this pathway might be responsible,
in part, for circadian abnormalities during prion disease pathogenesis. Progressive circadian disruption
is observed in FFI patients, evidenced by decreasing plasma melatonin levels with disease advancement
and complete loss of circadian rhythm by end-stage FFI [18,69]. A case study of one FFI patient
reported normal function of the SCN, as evidenced by normal core body temperature rhythms
and appropriate sleep stage timing, but dissociation of the circadian rhythms for melatonin and
cortisol [69]. This suggests normal light/dark entrainment and SCN oscillatory activity, but a
“functional interference” somewhere in the retino-pineal tract between the SCN and pineal gland
function [69].
Reports of circadian phase-shifts and dysregulated melatonin expression in PrPC dysfunction,
supported by the above experimental and clinical findings [10,68], suggest a delay in the synthesis
or release of melatonin. Establishing the point at which PrPC interacts with the melatonin-synthesis
pathway, whether at the pinealocyte or at structure upstream in the circuit, is therefore essential for
revealing the mechanism underlying the abnormal circadian cycling.
As indicated earlier and depicted in Figure 1, functionally, between the SCN and pineal gland lie
three structures: the hypothalamic paraventricular nucleus (PVN), the intermediolateral nucleus
(IML) of the thoracic spinal column and the superior cervical ganglion (SCG) at the top of the
sympathetic chain. The main neurotransmitters released by each structure are vasopressin/oxytocin,
acetylcholine and noradrenaline respectively [47]. The fact that melatonin is still synthesized at healthy
levels in models of PrP−/− and early-stage TSEs, albeit with an altered expression pattern, suggests
that the structures are capable of neurotransmission of reasonable fidelity, but the phasing may be
compromised in some way. It has been demonstrated that noradrenaline dysregulation is implicated
in TSE pathology; for example, after oral and intraperitoneal prion inoculation, PrPSc neuroinvasion
follows a selective route from the periphery via sympathetic nerves to the brain [70,71]. Noradrenergic
cell death [72] and dramatically altered noradrenaline levels in specific brain regions (cerebral cortex,
cerebellum, pons) and plasma following intraperitoneal or intracerebral inoculation [71–74] have also
been demonstrated in experimental models of prion disease. However, these effects on noradrenaline
expression and neurotransmission have not been demonstrated in PrP−/− models, which suggests
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the specific targeting of the noradrenergic system is the result of PrPSc pathology, not a loss of PrPC
function in disease.
If neurotransmission throughout the retino-pineal tract is unchanged in PrP−/−, then the
point of melatonin dysregulation or synthesis delay must be at the SCG-pinealocyte synapse,
or due to a dysfunction at some point downstream and within the melatonin-synthesis signaling
pathway (see Figure 2). Despite experimental evidence for PrP mRNA upregulation within the
pinealocyte during the subjective night [75], no studies have specifically explored PrPC interactions or
co-localization at the pinealocyte. One scenario that might explain the melatonin phase shift exhibited
by clinical and experimental models of prion dysfunction is if compromised PrPC function causes
dysregulation at the point of serotonin acetylation within the melatonin synthesis pathway. Serotonin is
acetylated by the enzyme aralkylamine N-acetyltransferase (AA-NAT), whose activity acts as the
rate-limiting step of melatonin synthesis [76]. The AA-NAT gene contains a cAMP-responsive element
(cre) within its promoter region which, when stimulated by increased levels of cAMP, drives enzymatic
expression and activity [77]. Levels of pinealocyte cAMP increase in response to noradrenergic, and to
a lesser degree, dopaminergic, binding respectively with adrenergic and D1 receptors [77,78].
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Decarboxylation of 5-hydroxytryptophan gives rise to serotonin. SCG afferents, which project to
the pineal adjacent to capillaries, release noradr naline in o the pineal perivascular spa e, where
the neurotransmitter binds to α1B nd β1-adr noceptors o the pinealocyt m mbra e. Coincident
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into the circulation, where it has a biological half-life of ~45 min in humans and ~20 min in rats, before
hepatic metabolism and urinal metabolite excretion.
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AA-NAT activity determines melatonin synthesis lag [79], and a significant association between
AA-NAT polymorphisms and delayed phase sleep disorder has been shown [76]. Intriguingly, PrPC has
continually been proposed to act as a cell-surface scaffolding protein and in this role it may influence
AA-NAT activity indirectly through modulating the activity of pinealocyte G protein-coupled receptor
(GPCR) complexes. The GPCRs can be divided according to whether they couple with the Gαi protein
subunit, which inhibits cAMP production and adenylyl cyclase activity, or with the Gαs subunit,
which inversely stimulates cAMP and adenylyl cyclase activity. Of the main GPCRs expressed by the
pinealocyte, only the β-adrenergic and D1 GPCRs are Gαs-coupled [80,81]; it is, therefore, plausible
that PrPC associates with one or other of these two GPCRs (or both) as a scaffold protein and influences
their signaling cascade in pinealocytes. Supporting this, it has been demonstrated recently that PrPC
co-localizes with D1 receptors, and there is selective impairment of cAMP signaling in response to D1
stimulation in PrP−/− mice [78]. A lack of PrPC may act to reduce adenylyl cyclase activity, resulting
in an increased time for cAMP concentrations to reach a supra-threshold level. This would result in
dysregulation of AA-NAT, since the length of time taken to achieve optimal acetylation of serotonin
increases due to decreased AA-NAT enzymatic activity. Future investigations for a role of PrPC within
the circadian rhythm and regulation of melatonin synthesis should therefore investigate protein-protein
interactions of PrPC with noradrenergic and dopaminergic receptors, as well as analysis of analytes
and catalysts within the melatonin synthesis pathway, with a particular focus on levels of serotonin,
N-acetylserotonin and AA-NAT.
5. Conclusions
Clinical observation and experimental models of prion disease demonstrate clear circadian
dysfunction, suggesting a role for PrPC within the synthesis or regulation of melatonin release in
health. Drawing upon the limited literature, we propose that PrPC acts as a scaffold protein at
the pinealocyte, associating with the Gαs-coupled β-adrenergic and D1 GPCRs. In this hypothesis,
PrPC regulates the cAMP signaling cascade downstream of β-adrenergic/D1 activation, and in the
absence of PrPC (as evidenced by PrP−/− models), a phase shift in melatonin synthesis results due to
delayed AA-NAT enzymatic activity.
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